MedFocus Funds

Founder Michael Henson drives sourcing and investment committee decisions, supported by principal Ed Roschak. Henson draws on experience founding more than twenty medical-technology firms and chairing six IPOs. Roschak, a named inventor on over 40 patents, contributes technical due diligence and operational leadership.

MedFocus builds companies from physician-and-engineer networks that surface unmet clinical needs in cardiovascular, neurovascular, and orthopedic disease. The firm does not run a traditional scout program — it relies on Henson's three-decade Rolodex and Roschak's relationships from senior roles at Hewlett-Packard, Origin Medsystems, and Boston Scientific-acquired ventures.

MedFocus targets the earliest stage of device innovation — often pre-revenue, concept-stage companies it incubates internally. The firm builds management, handles regulatory groundwork, and seeks a trade sale or IPO path rather than participating in growth-stage or buyout rounds.

The public record does not detail a co-investment program. MedFocus's historical deals — including the Integra LifeSciences acquisition of Rebound Therapeutics and Orthopediatrics' purchase of ApiFix — were full acquisitions of incubated companies rather than syndicated venture rounds.

The management company serves as corporate officer for several portfolio firms, handling governance, risk management, contract management, and human resources. This centralization allows the incubator to reduce administrative burn for scientific founders while retaining operational control.